Stocks Health care GLMD
NASDAQ · Health careGalmed Pharmaceuticals Ltd. (GLMD)
It posted a net loss of $10.3M. At December 31, 2025 it held $4M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 31, 2026.
Key facts about Galmed Pharmaceuticals Ltd.
- Net worth
- Galmed Pharmaceuticals Ltd. has a market value (market cap) of $38.6M at the latest share price, and shareholders' equity of $15.8M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2020 revenue was $0, with a net loss of $28.8M.
- Cash flow
- In fiscal 2025 operations used $6.3M of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on March 31, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Galmed Pharmaceuticals Ltd. does
Galmed Pharmaceuticals Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GLMD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$10.3M | $2.39 | n/a |
| 2024 | n/a | -$7.5M | $8.08 | n/a |
| 2023 | n/a | -$6.9M | $30.00 | n/a |
| 2022 | n/a | -$17.9M | $127.80 | -$18.5M |
| 2021 | n/a | -$32.5M | $237.60 | -$32.9M |
| 2020 | $0 | -$28.8M | $243.00 | -$26.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Galmed Pharmaceuticals Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 9, 2026
- September 8, 2026
- September 3, 2026
- September 2, 2026Form POS AM filing POS AM
- September 2, 2026
- September 2, 2026
- August 19, 2026
- August 19, 2026
- August 17, 2026
- August 14, 2026
Insider trades
What the people running Galmed Pharmaceuticals Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Questions about GLMD
What does Galmed Pharmaceuticals Ltd. do?
Galmed Pharmaceuticals Ltd. is a company in the Health care sector, listed on NASDAQ as GLMD. Its shares trade on NASDAQ under the ticker GLMD.
What is Galmed Pharmaceuticals Ltd.'s net worth?
Galmed Pharmaceuticals Ltd. has a market value (market cap) of $38.6M at the latest share price, and shareholders' equity of $15.8M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Galmed Pharmaceuticals Ltd. profitable?
No. In fiscal 2025 it reported a net loss of $10.3M.
When did Galmed Pharmaceuticals Ltd. last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 31, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 9, 2026.
Similar companies
Compare GLMD with
Follow GLMD
Get an email when Galmed Pharmaceuticals Ltd. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Galmed Pharmaceuticals Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.